Emerging drugs for idiopathic thrombocytopenic purpura in adults

Expert Opinion on Emerging Drugs

Volumn 13, Issue 2, 2008, Pages 237-254

  Li, Xiaofang ^a   Hou, Ming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

AMG531; B cell targeted therapy; Eltrombopag; Idiopathic thrombocytopenic purpura; Intravenous immunoglobulin; ITP; Rituximab; Thrombopoietin receptor agonist

Indexed keywords

ABATACEPT; AKR 501; ALEMTUZUMAB; AMG 623; ANTOVA; AZATHIOPRINE; BELIMUMAB; CARIMUNE NF; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; ELTROMBOPAG; FC RECEPTOR IIB; GAMMAGARD LIQUID; GAMMAGARD SD; GMA 161; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; KIOVIG; LGD 4665; MDX 33; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; PRIVIGEN; PROTEIN KINASE SYK INHIBITOR; PRTX 100; R 788; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; REMIPLISTIM; RENODAPT; RG 1059; RG 2077; RHESUS D ANTIBODY; RITUXIMAB; RUPLIZUMAB; SANDGLOBIN; SANDGLOBULIN; SB 559448; SM 101; STAPHYLOCOCCUS PROTEIN A; TORALIZUMAB; TPIAO; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; YM 477;

ACNE; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ALOPECIA; AMENORRHEA; ANTIBODY PRODUCTION; ARTERY THROMBOSIS; ASEPTIC MENINGITIS; BLEEDING; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DIARRHEA; DIZZINESS; DROWSINESS; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; EYE PAIN; FATALITY; FEVER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEMOLYSIS; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INFECTION; INFERTILITY; INTRAVASCULAR HEMOLYSIS; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LUNG INSUFFICIENCY; MUSCLE RIGIDITY; MYOPATHY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PSYCHOSIS; REVIEW; SEBORRHEA; SECOND CANCER; SIDE EFFECT; SODIUM RETENTION; STOMACH DISEASE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT PLANNING; TREMOR; VOICE CHANGE; VOMITING; WEIGHT GAIN;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; DRUG DESIGN; HUMANS; MACROPHAGES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 46849090730     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.2.237     Document Type: Review

References (100)

1. Levine SP. Thrombocytopenia. In: Greer JP, Foerster J, Lukens JN, et al., editors, Wintrobe's clinical haematology. 11th edition. Philadelphia: Lippincott Williams & Wilkins. Reprinted by Jinan, PRC: Shandong Science & Technology Press; 2004. p. 1529-72
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008
3. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40
4. Provan D, Newland A, Bolton-Maggs P, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-96
5. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-13
6. Neylon AJ, Saunders PWG, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966-74
7. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1-10
8. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37:239-48
9. Coopamah M, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003;17:69-80
10. Andersson PO, Wadenvik H. Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy. Expert Rev Mol Med 2004;6:1-17
11. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998;102:1393-402
12. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-4
13. Zhang F, Chu X, Wang L, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006;76:427-31
14. Catani L, Fagiolia ME, Tazzari PL, et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006;34:879-87
15. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245-54
16. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005;105:215-8
17. Hou M, Andersson PO, Stockelberg D, et al. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol 1998;101:420-4
18. Heyns AP, Badenhorst PN, Lotter MG, et al. Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111 In-labeled platelets and homologous 51 Cr-labeled platelets differ. Blood 1986;67:86-92
19. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887-95
20. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364-9
21. + T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 2007;139:605-11
22. Andemariam B, Psaila B, Bussel JB. Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program 2007;2007:106-13
23. Nomura S, Matsuzaki T, Ozaki Y, et al. Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood 1998;91:3616-22
24. van Sorge NM, van der Pol WL, van de Winkel JG. Fcgamma R polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003;61:189-202
25. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004;124:91-6
26. Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001;98:130-9
27. Franchini M, Cruciani M, Mengoli C, et al. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:237-46
28. Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-54
29. Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991;77:31-3
30. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-51
31. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemos 2006;8:1664-72
32. Vesely SK, Perdue JJ, Rizvi MA, et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004;140:112-20
33. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33
34. Kuwana M, Ikeda Y. Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. Int J Hematol 2006;84:309-15
35. Veneri D, De Matteis G, Solero P, et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets 2005;16:307-11
36. Maeda S, Ogura K, Yoshida H, et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut 1998;42:338-43
37. Stasi R, Stipa E, Masi M, et al. Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-42
38. Sailer T, Lechner K, Panzer S, et al. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006;91:1041-5
39. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-8
40. Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007;29:950-62
41. Silverman GJ, Weissman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92
42. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42
43. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9
44. Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 2007;14:642-6
45. Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003;63:1229-43
46. Lim SH, Hale G, Marcus RE, et al. CAM PATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 1993;84:542-4
47. Liossis SNC, Sfikakis PP. Costimulation blockade in the treatment of rheumatic diseases. Biodrugs 2004;18:95-102
48. Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD 154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004;103:1229-36
49. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-16
50. Bussel JB, Kuter DJ, George JN, et al. AMG531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-81
51. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006;135:547-53
52. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
53. Kaushansky K. Small molecule mimics of hematopoietic growth factors: improving on Mother Nature? Leukemia 2001;15:673-4
54. Jenkins J, Williams D, Deng Y.et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-41
55. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47
56. Repeated exposure to eltrombopag in adults with idiopathic thrombocytopenic purpura (REPEAT). NCT00424177. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00424177?term= NCT00424177&rank=1
57. RAISE, randomized placebo-controlled idiopathic thrombocytopenic purpura (ITP) study with eltrombopag. NCT00370331. Available from: http://www. clinicaltrials.gov/ct2/show/NC T00370331?term=NCT00370331&rank=
58. Advances in the treatment of immune thrombocytopenic purpura: report from the 2006 American Society of Hematology Meeting. Available from: http://professional.cancerconsultants.com/conference_ash_2006.aspx?id=38854
59. Study of AKR-501 tablets taken orally once daily for 28 days in patients with chronic ITP NCT00441090. Available from: http://www.clinicaltrials.gov/ct2/ show/NC T00441090?term=NCT00441090&rank=1
60. Ligand presents positive LGD-4665 Phase I clinical trial results at the American Society of Hematology Annual Meeting (ASH). Available from: http://investors.ligand.com/releasedetail. cfm?ReleaseID=280413
61. Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody. N Engl J Med 1986;314:1236-9
62. Medarex and Aventis Behring announce positive clinical trial results for new autoimmune disease drug. Available from: http://www.medarex.com/cgi-local/ item.pl/20001204-555458
63. Rigel R788 raises platelet counts in immune thrombocytopenic purpura (ITP) patients in Phase 2 study. Available from: http://ir.rigel.com/phoenix. zhtml?c=120936&p=irol-newsArticle&ID= 1075637&highlight
64. SuppreMol receives orphan drug designation for SM101. Available from: http://www.biospace.com/news_story. aspx?NewsEntityId=69497
65. Protalex reports clinical progress of PRTX-100 in rheumatoid arthritis and idiopathic thrombocytopenic purpura. Available from: http://prtx.client. shareholder.com/releasedetail.cfm? ReleaseID=251389
66. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Trans Med Rev 2003;17:241-51
67. Sorensen R. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm 2007;13:278-83
68. CSL Behring announces FDA approval of Privigen™-First proline-stabilized 10 percent liquid IVIg. Available from: http://www. cslbehring.com/s1/cs/ enco/1151517263302/news/1182280875254/prdetail.htm
69. Kallenberg CGM. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin Exp Immunol 2007;150:437-41
70. Crow AR, Song S, Siragam V, Lazarus AH. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer 2006;47:710-3
71. Siragam V, Crow AR, Brine D, et al. Intravenous immunoglobulin ameliorates ITP via activating Feγ receptors on dendritic cells. Nat Med 2006;12:688-92
72. Zaja F, Vianelli N, Battista M, et al. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006;34:571-2
73. Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-8
74. Stasi R, Stipa E, Forte V, et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:3872-3
75. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007;110:2924-30
76. Perrotta AL. Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost 2006;12:97-100
77. Kuter DJ, Begley CG. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood 2002;100:3457-69
78. Zhang XL, Peng J, Sun JZ, et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost 2008;6:158-65
79. Sutherland AP, Mackay F, Mackay CR. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 2006; 112:774-86
80. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235-46
81. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007;136:309-14
82. Yu HM, Liu YF, Hou M. BAFF-an essential survival factor for B cells: links to genesis of ITP and may be of therapeutic target. Med Hypotheses 2008;70:40-2
83. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52
84. + regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007;78:139-43
85. + T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007;120:187-93
86. + regulatory T cells in mice: potential implication for the treatment of autoimmune diseases. J Mol Med 2007;85:1263-70
87. Available from: http://www.clinicaltrials.gov; http://www.pdsa.org/itp- clinical-trials/index.html
88. Freedman J, Garvey MB, Elinder G, Blanchette VS. Directions for research in autoimmune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998;424:82-4
89. Guo CS, Chu XX, Shi Y, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007;27:557-62
90. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenicpurpura with high-dose dexamethasone. N Engl J Med 2003;349:831-6
91. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dosedexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007;109:1401-7
92. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003;28:249-55
93. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532-7
94. Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Int Med 1989;111:723-9
95. Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol 2007;29:347-51
96. Peng J, Liu C, Liu D, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 2003;101:2721-6
97. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003;70:353-7
98. Zhao YQ, Wang QY, Zhai M, et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi (Chin) 2004;43:608-10
99. Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100:728-30
100. Goodnough LT, Shander AS. Recombinant factor VIIa: safety and efficacy. Curr Opin Hematol 2007;14:504-9